Biotech companies must quickly
convert new leads into purified therapeutics for clinical trials
and ultimately for the market. A key goal of the pilot process
facility is to make GMP compliant material for testing and
demonstrate a process scale-up essential to manufacturing plant
design. With an ever-increasing range of biologics (therapeutic
proteins and fragment, peptides, viruses and viral capsids, naked
DNA, and polysaccharides) expressed by a number of host cells
(bacterial, yeast, mammalian, insect, and plant cells), the
industry needs a versatile, scalable solid liquid separator to
process drugs for clinical studies. Centrifugation meets this
criteria.
